Groupama Asset Managment Trims Stock Position in Jazz Pharmaceuticals PLC $JAZZ

Groupama Asset Managment cut its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 70.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,576 shares of the specialty pharmaceutical company’s stock after selling 6,142 shares during the quarter. Groupama Asset Managment’s holdings in Jazz Pharmaceuticals were worth $340,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Farther Finance Advisors LLC boosted its stake in shares of Jazz Pharmaceuticals by 754.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company’s stock valued at $35,000 after purchasing an additional 234 shares in the last quarter. Danske Bank A S bought a new position in Jazz Pharmaceuticals in the third quarter worth about $40,000. Quent Capital LLC purchased a new stake in Jazz Pharmaceuticals in the third quarter worth about $44,000. Geneos Wealth Management Inc. lifted its holdings in Jazz Pharmaceuticals by 57.6% in the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock worth $47,000 after buying an additional 137 shares during the period. Finally, Caitong International Asset Management Co. Ltd boosted its position in Jazz Pharmaceuticals by 1,383.3% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 356 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 332 shares in the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have weighed in on JAZZ. Truist Financial upped their target price on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a report on Monday, January 12th. Piper Sandler lifted their price target on Jazz Pharmaceuticals from $219.00 to $232.00 and gave the company an “overweight” rating in a research report on Thursday. Wells Fargo & Company upped their price target on Jazz Pharmaceuticals from $235.00 to $250.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Needham & Company LLC increased their price objective on Jazz Pharmaceuticals from $210.00 to $235.00 and gave the stock a “buy” rating in a report on Monday, January 12th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a report on Monday, December 29th. Thirteen analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $215.38.

Insider Activity

In related news, Director Norbert G. Riedel sold 3,415 shares of the stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $192.00, for a total transaction of $655,680.00. Following the sale, the director directly owned 7,024 shares of the company’s stock, valued at approximately $1,348,608. This represents a 32.71% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Patricia Carr sold 1,287 shares of the firm’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $182.94, for a total transaction of $235,443.78. Following the sale, the chief accounting officer owned 6,512 shares of the company’s stock, valued at approximately $1,191,305.28. This represents a 16.50% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 68,015 shares of company stock worth $13,037,486. 4.30% of the stock is currently owned by company insiders.

Jazz Pharmaceuticals Stock Performance

Jazz Pharmaceuticals stock opened at $180.62 on Friday. Jazz Pharmaceuticals PLC has a twelve month low of $95.49 and a twelve month high of $198.00. The company has a quick ratio of 1.67, a current ratio of 1.86 and a debt-to-equity ratio of 1.00. The company has a market capitalization of $11.12 billion, a P/E ratio of -30.25, a PEG ratio of 0.33 and a beta of 0.22. The stock’s 50 day moving average is $173.81 and its 200 day moving average is $158.09.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Tuesday, February 24th. The specialty pharmaceutical company reported $6.64 EPS for the quarter, topping the consensus estimate of $6.49 by $0.15. Jazz Pharmaceuticals had a positive return on equity of 6.87% and a negative net margin of 8.35%.The business had revenue of $1.20 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same period in the previous year, the company posted $6.51 earnings per share. The company’s revenue for the quarter was up 8.1% compared to the same quarter last year. On average, equities research analysts predict that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.